Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
Life Sci. 2022 Oct 15;307:120874. doi: 10.1016/j.lfs.2022.120874. Epub 2022 Aug 10.
The innate immune system is a primary protective line in our body. It confers its protection through different pattern recognition receptors (PRRs), especially toll like receptors (TLRs). Toll like receptor 9 (TLR9) is an intracellular TLR, expressed in different immunological and non-immunological cells. Release of cellular components, such as proteins, nucleotides, and DNA confers a beneficial inflammatory response and maintains homeostasis for removing cellular debris during normal physiological conditions. However, during pathological cellular damage and stress signals, engagement between mtDNA and TLR9 acts as an alarm for starting inflammatory and autoimmune disorders. The controversial role of TLR9 in different diseases baffled scientists if it has a protective or deleterious effect after activation during insults. Targeting the immune system, especially the TLR9 needs further investigation to provide a therapeutic strategy to control inflammation and autoimmune disorders.
先天性免疫系统是人体的主要保护防线。它通过不同的模式识别受体(PRRs),特别是 Toll 样受体(TLRs)来提供保护。Toll 样受体 9(TLR9)是一种细胞内 TLR,在不同的免疫和非免疫细胞中表达。细胞成分的释放,如蛋白质、核苷酸和 DNA,可引发有益的炎症反应,并在正常生理条件下维持内环境稳定以清除细胞碎片。然而,在病理性细胞损伤和应激信号下,mtDNA 与 TLR9 之间的相互作用充当了启动炎症和自身免疫性疾病的警报。TLR9 在不同疾病中的争议作用令科学家感到困惑,如果在受到刺激后激活,它是具有保护作用还是有害作用。针对免疫系统,特别是 TLR9 的靶向治疗需要进一步研究,以提供一种控制炎症和自身免疫性疾病的治疗策略。